Jupiter Neurosciences (NASDAQ:JUNS) Trading Up 2.9% – Here’s Why

Jupiter Neurosciences, Inc. (NASDAQ:JUNS)’s share price was up 2.9% during mid-day trading on Thursday . The stock traded as high as $0.3990 and last traded at $0.3833. Approximately 71,225 shares traded hands during trading, a decline of 51% from the average daily volume of 144,907 shares. The stock had previously closed at $0.3724.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jupiter Neurosciences in a research note on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Jupiter Neurosciences Stock Performance

The company has a market capitalization of $13.91 million, a price-to-earnings ratio of -1.47 and a beta of 2.80. The company’s fifty day simple moving average is $0.47 and its two-hundred day simple moving average is $0.98.

Jupiter Neurosciences (NASDAQ:JUNS) last announced its quarterly earnings data on Wednesday, April 1st. The company reported ($0.07) earnings per share for the quarter. The business had revenue of $0.02 million for the quarter. Sell-side analysts anticipate that Jupiter Neurosciences, Inc. will post -0.06 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its holdings in Jupiter Neurosciences by 27.8% during the 4th quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock worth $135,000 after acquiring an additional 28,826 shares in the last quarter. Yorkville Advisors Global LP acquired a new position in shares of Jupiter Neurosciences in the 4th quarter valued at about $135,000. Finally, Allen Capital Group LLC acquired a new position in shares of Jupiter Neurosciences in the 4th quarter valued at about $31,000.

Jupiter Neurosciences Company Profile

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.